TEVA, US8816242098

Teva reports 44-week duvakitug data and Barclays targets Teva stock at USD 47.00

Published on 10/21/2026 at 10:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Duvakitug data covered 130 responders through week 44, while Teva stock awaits November 3 results. The trial reached 58 percent remission at 900 mg.

Clinical data and investor timetable

Teva and Sanofi evaluated 130 responders through 44 weeks on October 20, 2026.
Clinical remission reached 58 percent at the 900 mg dose in ulcerative colitis.
Barclays set a USD 47.00 target for Teva on October 15, 2026.
Teva scheduled third-quarter results for November 3, 2026.

TEVA, US8816242098, Illustration mit AI erstellt.

Teva Pharmaceutical Industries Limited (ISIN US8816242098) and Sanofi reported 44-week duvakitug data from 130 responders on October 20, 2026. The phase 2b extension study showed clinical remission of 58 percent at the 900 mg dose in ulcerative colitis. GlobeNewswire reported the results from the United European Gastroenterology Week presentation. Barclays analyst Glen Santangelo raised the target for Teva from USD 42.00 to USD 47.00 on October 15, 2026, according to Markets Insider.

Week 44 data sharpen the pipeline case

The study followed patients who had responded during a 14-week induction phase. In ulcerative colitis, the 900 mg group posted an 87 percent clinical response rate and 63 percent endoscopic improvement rate at week 44, compared with 82 percent and 59 percent at 450 mg. The higher dose also produced 58 percent clinical remission, versus 47 percent at 450 mg.

Three dated steps for Teva

On September 28, 2026, Teva announced U.S. approval of the denosumab biosimilar Degevma. On October 9, 2026, the company announced U.S. Food and Drug Administration approval of Weltruza, a once-monthly olanzapine injection. On October 20, 2026, Teva and Sanofi presented the duvakitug extension results, with 130 responders evaluated through week 44. These milestones move the investor discussion from regulatory access toward commercial execution and late-stage pipeline delivery.

What dates could move the story?

Teva scheduled its third-quarter 2026 results for November 3, 2026, with the conference call at 8:00 a.m. ET, according to StockTitan. Teva also scheduled an R&D Day for November 11, 2026, when management plans to discuss its research pipeline and its five-year value-creation potential, as GlobeNewswire reported on October 12, 2026.

Target and market context

Barclays' USD 47.00 target is above its prior USD 42.00 target, while the latest structured quote placed Teva's market capitalization at USD 47.6 billion as of October 21, 2026. The clinical data offer a measurable pipeline signal, but duvakitug remains investigational and its efficacy and safety have not been evaluated by a regulatory authority.

Teva stock has two near-term dates

The November 3 results will provide the next reported test of Teva's operating performance, followed by the November 11 R&D Day and further pipeline detail.